Targeting the endocannabinoid system in the treatment of fragile X syndrome
Nature Medicine2013Vol. 19(5), pp. 603–607
Citations Over TimeTop 1% of 2013 papers
Arnau Busquets-García, Maria Gomis‐González, Thomas Guegan, Carmen Agustín‐Pavón, Antoni Pastor, Susana Mato, Alberto Pérez-Samartı́n, Carlos Matute, Rafael de la Torre, Mara Dierssen, Rafaël Maldonado, Andrés Ozaita
Related Papers
- Fmr1 knockout mice: a model to study fragile X mental retardation. The Dutch-Belgian Fragile X Consortium.(1994)
- → Reduced FMRP and increased FMR1 transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers(2001)455 cited
- → Modeling fragile X syndrome in the <i>Fmr1</i> knockout mouse(2014)236 cited
- → DNA Methylation, Mechanisms of FMR1 Inactivation and Therapeutic Perspectives for Fragile X Syndrome(2021)46 cited
- → Intranuclear inclusions in a fragile X mosaic male(2013)40 cited